We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
The global south has once again been abandoned in its quest for vaccines
FT science editor Clive Cookson and global pharma correspondent Hannah Kuchler will answer your questions on Wednesday June 29
Short break in immune suppression treatment improves antibody production after vaccination while doing little harm
New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain
UK surge in infection rates, US faces recession, give women their Wimbledon due
Governments need to plan now for what could be a tough autumn
Pharma companies are hoping to catch up with rivals as they report promising trial results for jab
Mathematical modelling looked at deaths directly and indirectly linked to jabs
UK health agency investigating possibility of community transmission says risk to public ‘extremely low’
US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases
Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech
After years in retreat, the disease is once again on the rise across the continent
Children as young as six months old can begin receiving Pfizer or Moderna vaccines as soon as Monday
‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants
Recommendation by health agency advisory group marks shift in thinking of global health authorities
Only 1 per cent of the 10bn jabs delivered so far have been in low-income countries
US prepares to roll out jabs to last age group without access once regulatory approval is received
Commerce minister’s surprise remarks put WTO agreements at risk
At last week’s conference in LA, the real activity was outside on the streets
The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven
‘Next-generation’ jab delivers strong immune response against variants
First regional gathering in US in quarter century marred by squabbling over who could attend
US pharma company aims to roll out the new vaccine by late summer
German biotech’s promising early-stage results make it a sought-after partner
Protein-based vaccine is an alternative to mRNA technology used by BioNTech/Pfizer and Moderna
International Edition
